Literature DB >> 18374532

Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.

Jerrold L Abraham1, Charu Thakral.   

Abstract

Gadolinium (Gd) released from Gd-based MR contrast agents is the likely etiologic agent of nephrogenic systemic fibrosis (NSF). The biodistribution and kinetics of both chelated Gd and free Gd(3+) are reviewed, including demonstrations of Gd in tissues of NSF patients. The purpose of this review is to consolidate the available information on distribution, metabolism, excretion and retention of Gd with particular emphasis on the possible mechanisms in the development of NSF. We also raise serious concern about the growing tissue burden of Gd with the release of Gd from its chelates and its yet unknown consequences. The development of NSF as well as potential long-term consequences of tissue Gd retention represent a part of the spectrum of Gd toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374532     DOI: 10.1016/j.ejrad.2008.01.026

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  22 in total

1.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

2.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

Review 3.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide.

Authors:  Takao Koiso; Masaaki Yamamoto; Shinya Watanabe; Bierta E Barfod
Journal:  Neuroradiol J       Date:  2019-03-29

5.  Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration.

Authors:  M E Adin; L Kleinberg; D Vaidya; E Zan; S Mirbagheri; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-20       Impact factor: 3.825

Review 6.  Nanotechnology applications for glioblastoma.

Authors:  Edjah K Nduom; Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  Neurosurg Clin N Am       Date:  2012-06-14       Impact factor: 2.509

7.  Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats.

Authors:  Yì-Xiáng J Wáng; Joseph Schroeder; Heiko Siegmund; Jean-Marc Idée; Nathalie Fretellier; Gaëlle Jestin-Mayer; Cecile Factor; Min Deng; Wei Kang; Sameh K Morcos
Journal:  Quant Imaging Med Surg       Date:  2015-08

8.  The fate of Gd and chelate following intravenous injection of gadodiamide in rats.

Authors:  Grete Mørk Kindberg; Steinar Uran; Grete Friisk; Ivar Martinsen; Tore Skotland
Journal:  Eur Radiol       Date:  2010-02-16       Impact factor: 5.315

9.  Pediatric Patients Demonstrate Progressive T1-Weighted Hyperintensity in the Dentate Nucleus following Multiple Doses of Gadolinium-Based Contrast Agent.

Authors:  D R Roberts; A R Chatterjee; M Yazdani; B Marebwa; T Brown; H Collins; G Bolles; J M Jenrette; P J Nietert; X Zhu
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-28       Impact factor: 3.825

Review 10.  In vivo MRI cell tracking: clinical studies.

Authors:  Jeff W M Bulte
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.